EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cytek Biosciences's enterprise value is $158.1 Mil.
Cytek Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-12.0 Mil. Therefore, Cytek Biosciences's EV-to-EBITDA for today is -13.14.
The historical rank and industry rank for Cytek Biosciences's EV-to-EBITDA or its related term are showing as below:
CTKB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2671.1 Med: -6.4 Max: 433.98
Current: -13.14
During the past 6 years, the highest EV-to-EBITDA of Cytek Biosciences was 433.98. The lowest was -2671.10. And the median was -6.40.
CTKB's EV-to-EBITDA is ranked worse than 100% of 496
companies
in the Medical Devices & Instruments industry
Industry Median: 15.35
vs CTKB: -13.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cytek Biosciences EV-to-EBITDA Historical Data
The historical data trend for Cytek Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cytek Biosciences's EV-to-EBITDA
For the Medical Devices subindustry, Cytek Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's EV-to-EBITDA falls into.
Cytek Biosciences's current Enterprise Value is $158.1 Mil.
Cytek Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cytek Biosciences's PE Ratio (TTM) for today is calculated as:
Cytek Biosciences's share price for today is $3.30.
Cytek Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Cytek Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTKB has been successfully added to your 